- Compugen to Present at Upcoming Antibody Industrial Symposium
- Compugen to Receive Milestone Payment Triggered by Dosing of First Patient in the Second Phase 3 Trial Evaluating Rilvegostomig
- Compugen Reports First Quarter 2024 Results
- Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential
- Compugen Appoints David Silberman as Chief Financial Officer
- Compugen to Release First Quarter 2024 Results on Monday, May 20, 2024
- Compugen to Present New Clinical Data Showing COM701 Triple Combination Preliminary Anti-Tumor Activity in Microsatellite Stable Colorectal Cancer with Liver Metastases at ASCO 2024
More ▼
Key statistics
As of last trade Compugen Ltd (CGEN:TLV) traded at 699.80, -40.44% below its 52-week high of 1,175.00, set on Mar 05, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 656.30 |
---|---|
High | 702.90 |
Low | 656.30 |
Bid | 697.70 |
Offer | 699.90 |
Previous close | 656.30 |
Average volume | 89.36k |
---|---|
Shares outstanding | 89.53m |
Free float | 84.72m |
P/E (TTM) | -- |
Market cap | 618.81m ILS |
EPS (TTM) | -0.685 ILS |
Data delayed at least 20 minutes, as of Jul 16 2024 09:59 BST.
More ▼